METHOD FOR MONITORING INDIVIDUALS WITH RISK OF EARLY ATHEROSCLEROSIS AND SUFFERING FROM TYPE 2 DIABETES MELLITUS Russian patent published in 2014 - IPC G01N33/48 A61B5/107 A61B5/145 A61B5/155 A61B10/00 

FIELD: medicine.

SUBSTANCE: clinical medical history data are determined as follows: body weight index (BWI), kg/m²; waist circumference (WC), hip circumference (HC), waist-to-hip ratio, type 2 diabetes mellitus diagnosed in close relatives, arterial hypertension (AH) diagnosed. The laboratory data are measured as follows: plasminogen activator inhibitor-1 (PGAI-1), nmole/l; nitrogen oxide (NO) metabolites, %; resistin, ng/ml; insulin resistance (IR), mIU/ml; triglycerides (TG), mmole/l; high density lipoprotein cholesterol (HDLPC), mmole/l; fibrinogen, mg/dl; impaired fasting glucose (IFG), mmole/l; glycosylated haemoglobin (HbAlc), %; impaired glucose tolerance (IGT), mmole/l; homocystein (HC), mcmole/l; TNF-α, pg/ml; C-reactive protein, mg/l; endothelin and fibrinogen. The derived values are scored. The total score is used to determine a risk of atherosclerosis in the patients suffering from type 2 diabetes mellitus: extremely high, high, moderate and low. Taking into account the detected degree of risk, a dosage of aspirin and statins are determined, as well as a monitored mode of blood lipids, urinary albumin and blood creatinine is specified.

EFFECT: method enables determining a degree of risk of the atherosclerosis progression as shown by the clinical medical history and laboratory data, as well as specifying individual pathogenetic therapy for the patient that leads to reducing developing cardiovascular complications.

4 tbl, 1 ex